Key to Symbols

 Speaker Bio
 MOspace Entry (Details)
 Abstract (PDF)
 PowerPoint (PDF)
 Video Available (WMV)

Summit Purpose

  • New partnerships for research innovation
  • Identification of regulatory changes, legislation and institutional streamlining that will accelerate the transfer of knowledge from the laboratory to businesses
  • Ideas for product and service development that will guide private sector investment and demonstrate the need for a supportive government infrastructure
  • Insight about ways to collaborate with university researchers and other partners to transfer new technologies
  • New information on how to leverage the assets of universities, financial markets and business investment to create companies and jobs that will strengthen the economic foundations of the region

Business Journals Supplement

View the complete Missouri Regional Life Sciences Summit supplement from the Kansas City and St. Louis Business Journals. Click here to view.

National Movement of Clinical and Translational Science and Drug Discovery


Jamal Ibdah, senior associate dean for research and director, MU Institute for Clinical and Translational Science, University of Missouri-Columbia: "Translational Medicine: From Discovery To Health": Translational Medicine: From Discovery To Health

Sitta Sittampalam, professor, department of pharmacology, toxicology and therapeutics, University of Kansas Medical Center.

The Institute for Advancing Medical Innovations: Stepping into the future of drug discovery, delivery and biomedical engineering: Inspired by the opportunity to grow educational and entrepreneurial capacity, the Institute for Advancing Medical Innovation (IAMI) was established upon the belief that: ideas are translated to innovation to improve health. The Institute will focus on education and research that advances medical innovations. The result will ultimately accelerate the number and quality of new drugs, medical devices and drug–medical device combinations flowing from the investigators bench to the patient’s bedside. Guided by an advisory board of independent experts and staffed by experienced drug development and medical device leaders, the Institute is designed to create an unprecedented collaboration of resources and processes to support the following key objectives:

• Advance new, novel medical innovations for the diagnosis, treatment, prevention and control of human and animal disease;
• Create a culture of multi-disciplinary, multi-organizational collaboration focused on advancing medical innovations from discovery to commercialization;
• Conduct clinical proof of concept trials on new, novel medical innovations; and
• Prepare graduate and postdoctoral students for careers in development and commercialization of medical innovations.

The Institute was created with a gift of $8.1 million from the Kauffman Foundation with a challenge match of $8 million from KU Endowment.

Presented by the four campuses of the University of Missouri System
University of Missouri-ColumbiaUniversity of Missouri-Kansas CityMissouri University of Science and TechnologyUniversity of Missouri-St. Louis
Featuring experts from University of Missouri-Columbia, University of Missouri-Kansas City, Missouri University of Science and Technology, University of Missouri-St. Louis, University of Kansas, University of Kansas Medical Center, Kansas State University, St. Louis University, Washington University in St. Louis, Iowa State University and the University of Saskatchewan, as well as business leaders, venture capitalists and policy makers